Misplaced Pages

Lumacaftor: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 08:06, 3 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,071 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'StdInChI', 'StdInChIKey', 'CAS_number').← Previous edit Revision as of 08:07, 3 November 2011 edit undoBeetstra (talk | contribs)Edit filter managers, Administrators172,071 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: '').Next edit →
Line 27: Line 27:


<!--Identifiers--> <!--Identifiers-->
| CAS_number = <!-- blanked - oldvalue: 936727-05-8 --> | CAS_number = 936727-05-8
| ATCvet = | ATCvet =
| ATC_prefix = None | ATC_prefix = None
Line 38: Line 38:
| molecular_weight = 452.407 g/mol | molecular_weight = 452.407 g/mol
| smiles = CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O | smiles = CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O
| StdInChI = <!-- blanked - oldvalue: 1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31) --> | StdInChI = 1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)
| StdInChIKey = <!-- blanked - oldvalue: UFSKUSARDNFIRC-UHFFFAOYSA-N --> | StdInChIKey = UFSKUSARDNFIRC-UHFFFAOYSA-N
}} }}


Revision as of 08:07, 3 November 2011

{{Drugbox | IUPAC_name = 3-{6-{amino}-3-methylpyridin-2-yl}benzoic acid | image = VX-807 skeletal.svg | alt = | caption =

| tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Investigational | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number = 936727-05-8 | ATCvet = | ATC_prefix = None | ATC_suffix = | PubChem = 16678941 | DrugBank =

| C=24|H=18|F=2|N=2|O=5 | molecular_weight = 452.407 g/mol | smiles = CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O | StdInChI = 1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31) | StdInChIKey = UFSKUSARDNFIRC-UHFFFAOYSA-N }}

VX-807 is an experimental drug for the treatment of cystic fibrosis. The drug is designed to be effective in patients that have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease. F508del, meaning that the amino acid phenylalanin in position 508 is missing, is found in about 90% of cystic fibrosis patients.

References

  1. Pharmazeutische Zeitung (in German). 156 (37): 24–27. {{cite journal}}: Missing or empty |title= (help); Unknown parameter |authors= ignored (help)
This article has not been added to any content categories. Please help out by adding categories to it so that it can be listed with similar articles, in addition to a stub category. (November 2011)


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Lumacaftor: Difference between revisions Add topic